Varian (VAR) Buys Noona to Boost Oncology Software Services

Varian Medical Systems, Inc. (VAR) recently announced the acquisition of Noona Healthcare. Notably, Noona’s patient software app will help capture cancer patient-reported outcomes (PROs) and enable direct communication with patients. The buyout is likely to boost Varian’s Oncology Software Solutions business and fortify its foothold in the global oncology information system (OIS) market.

In fact, the California-based MedTech giant plans on combining its 360 Oncology SaaS platform with Noona's patient user interface with a view to actively engage patients with their cancer care team.

The company also plans to expand Noona's portfolio of real-world evidence-driven services, such as PROs to enable outcomes studies, clinical trials and digital therapeutics.

How Will Varian Gain?

Cloud-based service provider Noona’s user interface is designed to efficiently manage patients’ symptoms. It engages patients, collects PRO data and manages patient communications. Interestingly, it leads to improved clinical outcomes by reducing the frequency of hospitalization and emergency room visits.

Per management, this buyout strengthens Varian’s ties with lifesciences and pharmaceutical companies.

MarketsandMarkets predicts that the global OIS market is expected to reach $2.6 billion by 2019, at a CAGR of 8.5%.

Hence, Varian’s move has been a well-timed one.

Varian’s Oncology Software Services in Focus

Varian’s comprehensive oncology software provides a seamless flow of information for accurate, efficient and timely information helping to build a solid foundation for patient safety and well-being.

In fact, Oncology Systems forms the largest business segment of the company which contributed 94.1% to net revenues.

Some of the noteworthy platforms are 360 Oncology, Eclipse for Proton and Eclipse Treatment planning system.

For instance, Eclipse for Proton is an open platform offering a single solution for all planning modalities and supporting a variety of proton delivery systems.

For investors’ notice, the Proton therapy comes under Varian’s Particle therapy business, which has gained momentum on the ProBeam system.

Varian faces competition from MedTech bigwigs in the industry like Accuray Incorporated (ARAY), which also specialises in radiosurgery and radiation therapy systems for treatment of tumors in the body.

MedTech Adopts Cloud-Based Services

The field of healthcare is currently witnessing increasing digitization of patient records through cloud-based services. Healthcare companies are relying on cloud-based records since they are time-saving and cost efficient.

Some of the healthcare giants which are raking in billions through cloud-based services are Cerner Corporation (CERN), athenahealth (ATHN) and Allscripts Healthcare (MDRX).

Cerner’s HealtheIntent, athenahealth’s athenaNet and Allscripts’ FollowMyHealth patient engagement platform deserve a mention in this regard.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

 

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

 

Click here to see the 5 stocks >>

Varian Medical Systems, Inc. VAR recently announced the acquisition of Noona Healthcare. Notably, Noona’s patient software app will help capture cancer patient-reported outcomes (PROs) and enable direct communication with patients. The buyout is likely to boost Varian’s Oncology Software Solutions business and fortify its foothold in the global oncology information system (OIS) market.

 

In fact, the California-based MedTech giant plans on combining its 360 Oncology SaaS platform with Noona's patient user interface with a view to actively engage patients with their cancer care team.

 

The company also plans to expand Noona's portfolio of real-world evidence-driven services, such as PROs to enable outcomes studies, clinical trials and digital therapeutics.

 

How Will Varian Gain?

 

Cloud-based service provider Noona’s user interface is designed to efficiently manage patients’ symptoms. It engages patients, collects PRO data and manages patient communications. Interestingly, it leads to improved clinical outcomes by reducing the frequency of hospitalization and emergency room visits.

 

Per management, this buyout strengthens Varian’s ties with lifesciences and pharmaceutical companies.

 

MarketsandMarkets predicts that the global OIS market is expected to reach $2.6 billion by 2019, at a CAGR of 8.5%.

 

Hence, Varian’s move has been a well-timed one.

 

Varian’s Oncology Software Services in Focus

 

Varian’s comprehensive oncology software provides a seamless flow of information for accurate, efficient and timely information helping to build a solid foundation for patient safety and well-being.

 

In fact, Oncology Systems forms the largest business segment of the company which contributed 94.1% to net revenues.

 

Some of the noteworthy platforms are 360 Oncology, Eclipse for Proton and Eclipse Treatment planning system.

 

For instance, Eclipse for Proton is an open platform offering a single solution for all planning modalities and supporting a variety of proton delivery systems.

 

For investors’ notice, the Proton therapy comes under Varian’s Particle therapy business, which has gained momentum on the ProBeam system.

 

Varian faces competition from MedTech bigwigs in the industry like Accuray Inc. ARAY, which also specialises in radiosurgery and radiation therapy systems for treatment of tumors in the body.

 

MedTech Adopts Cloud-Based Services

 

The field of healthcare is currently witnessing increasing digitization of patient records through cloud-based services. Healthcare companies are relying on cloud-based records since they are time-saving and cost efficient.

 

Some of the healthcare giants which are raking in billions through cloud-based services are Cerner Corp. CERN and athenahealth ATHN.

 

Cerner’s HealtheIntent and athenahealth’s athenaNet deserve a mention in this regard.

 

5 Medical Stocks to Buy Now

 

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.

 

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Cerner Corporation (CERN) : Free Stock Analysis Report
 
athenahealth, Inc. (ATHN) : Free Stock Analysis Report
 
Varian Medical Systems, Inc. (VAR) : Free Stock Analysis Report
 
Accuray Incorporated (ARAY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research